Small-molecule IL4R antagonists for inflammatory skin disease therapy

Overview

This project addresses a major unmet need in the treatment of atopic dermatitis, psoriasis, and other chronic inflammatory skin conditions. Current leading therapies, such as Dupilumab, rely on injectable antibodies that block the IL4 and IL13 signaling pathways. While effective, these biologics are expensive, require subcutaneous administration, and have been associated with a range of adverse effects. The research team proposes to discover first-in-class small-molecule antagonists of the IL4 receptor (IL4R) that could be developed into oral or topical drugs, dramatically improving patient convenience, accessibility, and tolerability.

The effort combines ultra-large-scale virtual screening, AI-driven ADME and pharmacokinetic modeling, and experimental validation to identify drug-like compounds capable of blocking IL4R signaling. A successful program would deliver a novel therapeutic modality for a multi-billion-dollar market currently dominated by injectable biologics.

Technical specifications

• Ultra-large structure-based screening of over 10 billion compounds docked against an optimized 3D model of the IL4R heterodimer and its complex with IL13
• Binding pocket identification and refinement using proprietary molecular modeling techniques implemented in the ICM software platform
• AI and machine learning models for predicting ADME properties, pharmacokinetics, pharmacodynamics, off-target activities, and toxicity to prioritize drug-like candidates
• High-performance computing infrastructure enabling rapid docking, scoring, and screening at unprecedented library scale
• Experimental validation pipeline including in vitro and in vivo assays for IL4R activity, followed by one round of medicinal chemistry optimization based on results
• Validation strategy anchored by reproducing known weak IL4R antagonists (2 micromolar affinity) identified by MIT researchers in 2020, then improving potency through expanded screening

Technology readiness level

The program is at an early discovery stage, with the core hypothesis supported by clinical validation of IL4R as a therapeutic target (Dupilumab approval for atopic dermatitis and severe asthma) and prior proof-of-concept small-molecule hits from independent academic research. The computational pipeline for ultra-large library screening and ADME prediction has been established and published. Current activities focus on optimizing the IL4R structural model, validating screening protocols against known weak antagonists, and preparing to execute the full 10-billion-compound screen. Lead compound identification and experimental confirmation of IL4R inhibition represent the next major milestones, after which medicinal chemistry optimization and preclinical development would follow.